Европейский союз - исландский - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - Æxlishemjandi lyf - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - ceftazidimum inn - stungulyfs-/innrennslisstofn, lausn - 2 g

Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - ceftazidimum inn - stungulyfsstofn, lausn - 1 g

Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 40 mg

Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab - human fibrinogen; human factor xiii; bovine aprotinin; human thrombin; calcii chloridum; thrombin; protein - lausnir fyrir vefjalím

Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

sanofi-aventis norge as - enoxaparinum natricum inn - stungulyf, lausn - áfyllt sprauta 100 mg/ml

Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

sanofi-aventis norge as - enoxaparinum natricum inn - stungulyf, lausn - í hettuglösum 100 mg/ml

Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratoires thea s.a.s. - ketotifenum fúmarat - augndropar, lausn - 0,25 mg/ml

Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - fosphenytoinum dínatríum - stungulyf, lausn/innrennslisþykkni, lausn - 50 mg fe/ml

Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

essential pharma limited - haloperidolum dekanóat - stungulyf, lausn - 100 mg/ml